Our unique partnerships with academic thought leaders and experience in CNS drug development, positions Appello to deliver on the promise of translating groundbreaking science into novel therapies that can improve the lives of patients.
A Phase I clinical trial for a novel Parkinson’s therapeutic, AP-472, is underway. Originally developed at Vanderbilt University, AP-472 has the potential to significantly improve the debilitating effects associated with later stage Parkinson’s disease.
Our interest extends beyond Parkinson’s to include preclinical development programs targeting innovative therapies for other neurological conditions. We are currently investigating novel therapies for conditions such as Autism Spectrum Disorder (ASD), pain, addictive disorders, anxiety and PTSD, among others.
We seek to partner with patients, their families and caregivers to make a positive impact on the unmet needs of those affected by neurological conditions. To learn more about how we are making a difference in the lives of patients, click here.